Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 195 participants.

Also called NCT07271186

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 195 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07271186
  • EU CT 2026-527519-41-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07271186. Randomized; quadruple masking; primary purpose treatment. Start 2026-01-09 (actual); primary completion 2028-10-13 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
Acronym
ANCHOR-POC
Condition
Diabetic Kidney Disease (DKD)
Intervention (Drug)
ALN-ANG3
Intervention (Drug)
Evinacumab
Intervention (Drug)
Placebo
Lead sponsor
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07271186
Content hash
89f5b38bab61875aa49af5b9ad916ca53e0cd3a5be9da8e498010386c292bbda